Guideline Page and Request | Panel Discussion | References | Vote
--- | --- | --- | ---
**BINV-20**
**Internal request:**
Discuss the role of pertuzumab therapy as second-line option for patients with disease progression after trastuzumab-based therapy.

Based on the data noted in the references, the NCCN Panel expanded the recommendation to include consideration of one line of therapy containing trastuzumab plus pertuzumab with or without a cytotoxic agent (such as vinorelbine or taxane) in patients with disease progression after treatment with trastuzumab-based therapy without pertuzumab.


<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>